EADV Congress 2025: Late-Breaking Trials Preview

Among dermatologists and other clinicians in the skin health space, the European Academy of Dermatology and Venereology (EADV) Congress is more than just a yearly meeting—it is a venue at which new data can shift existing standards of care and redefine treatment approaches. The late-breaking abstract sessions each year during the EADV Congress bring forward findings that can help to not only inform decision-making but also spark debate, collaboration, and momentum across dermatology.

The 2025 EADV Congress, set to take place in Paris, France from September 17–20, is set to release a series of late-breaking findings spanning inflammatory skin disease and pigmentary disorders, with data that could impact both frontline practice and long-term research trajectories. These sessions will be an opportunity to gain firsthand insight into the science that will guide tomorrow’s treatment landscape for conditions such as psoriasis, atopic dermatitis, alopecia areata, and more.

With this in mind, the HCPLive team has identified 13 phase 2 and phase 3 late-breaking presentations for clinicians to watch at EADV 2025. These studies highlight the evolving innovation pipeline across dermatology and venereology.

Trials to Watch EADV Congress 2025

1. Long-term efficacy and complete scalp hair regrowth in patients with alopecia areata receiving ritlecitinib 50 mg QD up to 3 years in the ALLEGRO clinical trial program

Presentation Time: Thursday, September 18, 14:15 - 14:30 CEST
Presenter: Brett King, MD, PhD
Background Info: New long-term findings from the ALLEGRO program will highlight durability of response with ritlecitinib (Litfulo) in alopecia areata, with data extending out to 3 years. The analysis focuses on sustained scalp hair regrowth and the proportion of patients achieving complete response over time with the agent, which received approval from the FDA for treatment of severe alopecia areata in adults and adolescents 12 years and older in June 2023.1

2. Povorcitinib for Moderate to Severe Hidradenitis Suppurativa: Week 24 Interim Phase 3 Results

Presentation Time: Wednesday, September 17, 14:45 - 15:00 CEST
Presenter: Martina Porter, MD
Background Info: This phase 3 interim analysis will present 24-week efficacy and safety data for povorcitinib in patients with moderate to severe hidradenitis suppurativa. Results will provide insight into the potential role of this investigational JAK1 inhibitor in addressing an area of high unmet clinical need.2

In March 2025, Incyte announced both of the phase 3 STOP-HS trials, STOP-HS1 and STOP-HS2, met their primary endpoint at both tested doses (45 mg and 75 mg), with a significantly higher proportion of patients treated with povorcitinib once daily versus placebo achieved Hidradenitis Suppurativa Clinical Response.

3. Safety of delgocitinib cream in adult patients with Chronic Hand Eczema (CHE): pooled analysis of five phase 2b and phase 3 trials

Presentation Time: Thursday, September 18, 15:15 - 15:30 CEST
Presenter: Robert Bissonnette, MD
Background Info: A pooled analysis of 5 phase 2b and phase 3 trials will evaluate the safety of delgocitinib cream (Anzupgo) in adults with chronic hand eczema (CHE). The agent, an inhibitor of JAK1 and TYK2, received a historic approval in July 2025 as the first FDA-approved therapy for CHE.

The results of the EADV analysis aim to clarify its tolerability and support its potential as a long-term topical treatment option for this challenging condition.3

4. Baricitinib in the Treatment of Adults with Pyoderma Gangrenosum: A Phase II Open Label Trial

Presentation Time: Wednesday, September 17, 14:30 - 14:45 CEST
Presenter: Alex Ortega Loayza, MD
Background Info: This phase 2 open-label trial will assess the efficacy and safety of baricitinib (Olumiant) in adults with pyoderma gangrenosum. The study aims to explore the agent, which boasts approvals for rheumatoid arthritis and alopecia dating back to 2018 and 2022, respectively, in managing this rare and difficult-to-treat inflammatory skin disorder.4

5. Efficacy and safety of izokibep, a novel interleukin-17A inhibitor, in moderate to severe hidradenitis suppurativa: Week 16 results from a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Presentation Time: Wednesday, September 17, 15:00 - 15:15 CEST
Presenter: Kim A. Papp, MD, PhD
Background Info: Week 16 results from this phase 3 trial will detail the efficacy and safety of izokibep, a novel small interleukin-17A inhibitor, in patients with moderate to severe hidradenitis suppurativa. In August 2024, Acelyrin announced izokibep demonstrated statistically significant responses across multiple efficacy endpoints at 12 weeks, including the trial's primary outcome of HiSCR75.

Data from the study will add to the growing body of evidence on IL-17 blockade as a therapeutic strategy in this challenging disease.5

6. IL-22RA1 antagonism with temtokibart provides significant early and sustained improvements in atopic dermatitis: results from a phase 2b dose-finding trial

Presentation Time: Wednesday, September 17, 15:15 - 15:30 CEST
Presenter: Stephan Weidinger, MD, PhD
Background Info: This phase 2b dose-finding trial will present data on temtokibart, an IL-22RA1 antagonist, showing early and sustained improvements in patients with atopic dermatitis. In May 2025, LEO Pharma announced positive topline data from the trial indicating use of temtokibart was associated with improvement in achieved the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score. The results aim to highlight the potential of targeting IL-22 signaling as a novel approach in managing moderate-to-severe disease.6

7. Temtokibart, an IL-22RA1 Monoclonal Antibody broadly dampens gene expression markers of activated immune pathways in Atopic Dermatitis: Results from a Phase 2b Trial Subgroup Analysis

Presentation Time: Wednesday, September 17, 15:30 - 15:45 CEST
Presenter: Ester Del Duca, MD
Background Info: This subgroup analysis will explore how data from the phase 2b dose-finding trial demonstrates temtokibart's modulation of gene expression and its association with activated immune pathways in atopic dermatitis. The findings aim to shed light on the molecular mechanisms underlying its clinical efficacy, which will be integral to its integration in treatment algorithms for the heterogenous disease.7

8. Efficacy and Safety of Ruxolitinib Cream in Patients With Prurigo Nodularis: Pooled Results From the Phase 3 TRuE-PN1 and TRuE-PN2 Randomized, Vehicle-Controlled Studies

Presentation Time: Wednesday, September 17, 16:00 - 16:15 CEST
Presenter: Sonja Ständer, MD
Background Info: Pooled phase 3 data will assess the efficacy and safety of ruxolitinib cream 0.15% (Opzelura) in patients with prurigo nodularis. The TRuE-PN1 and TRuE-PN2 trials captured the attention of the dermatology community in March 2025 when Incyte announced the TRuE-PN1 trial had met its primary endpoint, but the TRuE-PN2 trial failed to achieve statistical significance for the same outcome due to high placebo response. The results are expected to provide a comprehensive view of its potential as a targeted topical therapy for this chronic, intensely pruritic condition.8

9. Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults (Weeks 24-52) and Continuous Treatment in Adolescents (Through Week 52) From the Phase 3, ICONIC-LEAD Trial

Presentation Time: Wednesday, September 17, 16:15 - 16:30 CEST
Presenter: Jennifer Soung, MD
Background Info: The ICONIC-LEAD trial will present data on the durability of response with icotrokinra in adults and adolescents with moderate-to-severe plaque psoriasis. ICONIC-LEAD is a multicenter, randomized, double-blind, placebo-controlled study, with 684 participants aged 12 years and older enrolled at 170 sites globally. Icotrokinra is a first-in-class, targeted oral peptide designed to selectively bind the interleukin (IL)-23 receptor and inhibit IL-23 pathway signaling. These findings will highlight both treatment withdrawal and continuous therapy to explore long-term disease control.9

10. Bimekizumab efficacy and safety through 3 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and their open-label extension BE HEARD EXT

Presentation Time: Wednesday, September, 17:00 - 17:15 CEST
Presenter: John R. Ingram, MD, PhD
Background Info: Long-term data from BE HEARD I&II and the open-label extension will assess the sustained efficacy and safety of bimekizumab in hidradenitis suppurativa over three years. Bimekizumab is the first and only approved medication designed to selectively inhibit both IL-17A and IL-17F among patients. These new results may help to inform long-term management strategies for this chronic condition.10

11. Molecular and Clinical Effects of Oral ATI-2138, an ITK/JAK3 inhibitor, in Moderate-to-Severe Atopic Dermatitis: Sub-study of a Phase 2a Open-Label, Single-Arm Trial

Presentation Time: Thursday, September 18, 14:15 - 14:30 CEST
Presenter: Jessica Beaziz Tordjman, MD
Background Info: This sub-study evaluates both molecular and clinical outcomes of oral ATI-2138 in moderate-to-severe atopic dermatitis. ATI-2138 is a novel pharmacologic agent which acts as a dual inhibitor of interleukin-2-inducible T cell kinase (ITK) and JAK3. These late-breaking findings may provide insights into how ITK/JAK3 inhibition translates to disease improvement at the cellular level.11

12. DELTA TEEN Phase 3 trial: Efficacy and Safety of Delgocitinib Cream in Adolescents with Moderate to Severe Chronic Hand Eczema

Presentation Time: Thursday, September 18, 14:30 - 14:45 CEST
Presenter: Sonja Molin, MD
Background Info: The DELTA TEEN trial will report on the efficacy and safety of delgocitinib cream in adolescents with chronic hand eczema. DELTA TEEN is a 16-week, phase 3 DELTA TEEN trial that used a randomized, double-blind, vehicle-controlled, parallel-group, multi-site design. Investigators explored delgocitinib's efficacy and safety with twice-daily use. Their primary endpoint was an Investigator’s Global Assessment for chronic hand eczema treatment success (IGA-CHE TS) at Week 16. These data may help to expand treatment options for this age group in a condition that is often challenging to manage.12

13. Initial “Super Response” to Tralokinumab Leads to Stable Long-term Response in Patients with Moderate-to-Severe Atopic Dermatitis: Responder and Predictor Analysis from the ECZTRA 3 & ECZTEND Trials

Presentation Time: Friday, September 19, 15:30 - 15:45 CEST
Presenter: Andrew Blauvelt, MD
Background Info: This analysis will explore how early “super responders” to tralokinumab maintain long-term control of moderate-to-severe atopic dermatitis. The 32-week ECZTRA 3 study assessed the effectiveness and safety of tralokinumab plus topical corticosteroids (TCS) versus placebo plus TCS. ECZTEND was an open-label, single-arm, multi-center, long-term extension study designed to assess the tralokinumab in patients with atopic dermatitis who had participated in prior tralokinumab clinical research. These late-breaking data will examine predictors of sustained response, potentially guiding patient selection and treatment optimization.13

For more information from the EADV Congress 2025 and other conference coverage, view our latest coverage page.

Editor's note: The summaries of these data were edited with the help of AI tools.

References

1. Long-term efficacy and complete scalp hair regrowth in patients with alopecia areata receiving ritlecitinib 50 mg QD up to 3 years in the ALLEGRO clinical trial program. Presented at: EADV Congress 2025. September 17 – 20, 2025. Paris, France.

2. Povorcitinib for Moderate to Severe Hidradenitis Suppurativa: Week 24 Interim Phase 3 Results. Presented at: EADV Congress 2025. September 17 – 20, 2025. Paris, France.

3. Safety of delgocitinib cream in adult patients with Chronic Hand Eczema (CHE): pooled analysis of five phase 2b and phase 3 trials. Presented at: EADV Congress 2025. September 17 – 20, 2025. Paris, France.

4. Baricitinib in the Treatment of Adults with Pyoderma Gangrenosum: A Phase II Open Label Trial. Presented at: EADV Congress 2025. September 17 – 20, 2025. Paris, France.

5. Efficacy and safety of izokibep, a novel interleukin-17A inhibitor, in moderate to severe hidradenitis suppurativa: Week 16 results from a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Presented at: EADV Congress 2025. September 17 – 20, 2025. Paris, France.

6. IL-22RA1 antagonism with temtokibart provides significant early and sustained improvements in atopic dermatitis: results from a phase 2b dose-finding trial. Presented at: EADV Congress 2025. September 17 – 20, 2025. Paris, France.

7. Temtokibart, an IL-22RA1 Monoclonal Antibody broadly dampens gene expression markers of activated immune pathways in Atopic Dermatitis: Results from a Phase 2b Trial Subgroup Analysis. Presented at: EADV Congress 2025. September 17 – 20, 2025. Paris, France.

8. Efficacy and Safety of Ruxolitinib Cream in Patients With Prurigo Nodularis: Pooled Results From the Phase 3 TRuE-PN1 and TRuE-PN2 Randomized, Vehicle-Controlled Studies. Presented at: EADV Congress 2025. September 17 – 20, 2025. Paris, France.

9. Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults (Weeks 24-52) and Continuous Treatment in Adolescents (Through Week 52) From the Phase 3, ICONIC-LEAD Trial. Presented at: EADV Congress 2025. September 17 – 20, 2025. Paris, France.

10. Bimekizumab efficacy and safety through 3 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and their open-label extension BE HEARD EXT. Presented at: EADV Congress 2025. September 17 – 20, 2025. Paris, France.

11. Molecular and Clinical Effects of Oral ATI-2138, an ITK/JAK3 inhibitor, in Moderate-to-Severe Atopic Dermatitis: Sub-study of a Phase 2a Open-Label, Single-Arm Trial. Presented at: EADV Congress 2025. September 17 – 20, 2025. Paris, France.

12. DELTA TEEN Phase 3 trial: Efficacy and Safety of Delgocitinib Cream in Adolescents with Moderate to Severe Chronic Hand Eczema. Presented at: EADV Congress 2025. September 17 – 20, 2025. Paris, France.

13. Initial “Super Response” to Tralokinumab Leads to Stable Long-term Response in Patients with Moderate-to-Severe Atopic Dermatitis: Responder and Predictor Analysis from the ECZTRA 3 & ECZTEND Trials. Presented at: EADV Congress 2025. September 17 – 20, 2025. Paris, France.